ANI Pharma appoints Matt Leonard to board; Nash not to seek reelection

ANI PHARMACEUTICALS INC

Board appointed Matt Leonard as director, effective August 21, 2023, with term expiring at 2024 annual meeting.
Leonard is Chief Pharmacy Strategy Officer at Capsule; previously held senior roles at CVS Health and Covetrus.
Leonard receives initial restricted stock award of $435,000 vesting over three years under the 2022 Stock Incentive Plan.
David B. Nash will not seek reelection at the 2024 annual meeting; continues as director until then.
Nash's decision not due to any disagreement with the company on operations, policies, or practices.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David B. Nash

Director

ANIP · ANI PHARMACEUTICALS INC

Filed: August 23, 2023, 7:59 PM ET

On August 22, 2023, Dr. David B. Nash, M.D. informed the Board of his decision not to seek reelection as a director on the Board at the Company’s 2024 Annual Meeting of Stockholders

Appointed

Matt Leonard

Director

ANIP · ANI PHARMACEUTICALS INC

Effective: 2023-08-21
Filed: August 23, 2023, 7:59 PM ET

appointed Matt Leonard to serve on the Board as a director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David B. Nash departed as Director at ANI PHARMACEUTICALS INC.

Action: not seeking reelection
Role: Director

Exact text from the filing

On August 22, 2023, Dr. David B. Nash, M.D. informed the Board of his decision not to seek reelection as a director on the Board at the Company’s 2024 Annual Meeting of Stockholders

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Matt Leonard was appointed as Director at ANI PHARMACEUTICALS INC.

Action: appointed
Role: Director

Exact text from the filing

appointed Matt Leonard to serve on the Board as a director

View on SEC.gov

ANI PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-094371

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.